The clinical trials will help advance the development of a critical diagnostic tool. Credit: fernando zhiminaicela from Pixabay.

Medical health wearables technology company EnLiSense CCM has obtained funding from the Crohn’s & Colitis Foundation’s IBD Ventures programme for the development of its IBD AWARE product.

IBD AWARE is a real-time inflammation sweat sensor, which targets key biomarkers linked with inflammatory bowel disease (IBD). It is designed to track and monitor IBD activity in patients.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Andres Hurtado-Lorenzo, Crohn’s & Colitis Foundation Translational Research & IBD Ventures vice-president, said: “We are very enthusiastic about supporting EnLiSense clinical studies to further validate their groundbreaking sweat biosensor, following our initial academic investment in this technology via the Foundation’s Novel Technologies Initiative.”

The wearable device samples nano-litres of passive sweat. It also continuously measures and reports biomarkers including Calprotectin, C-Reactive protein, interleukin-6, interleukin-1 beta, tumour necrosis factor-alpha and cortisol.

EnLiSense will use the funds for further clinical studies to support product development and validation.

See Also:

The trials are expected to accelerate the development of a critical diagnostic tool, which can facilitate research and development to enable personalised treatment and therapies for IBD patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

EnLiSense CCM CEO Dr Sriram Muthukumar said: “IBD AWARE will provide patients and their clinicians with the real-time, actionable data they need to further the quality of life outcomes.

“IBD AWARE biomarkers would be able to identify those individuals at risk for the disease and be disease-specific; would be able to detect disease activity and monitor the effect of treatment and would have a prognostic value towards relapse or recurrence.”